Bacteria are among the most brilliant chemists on Earth. They are capable of producing a wealth of structurally diverse natural products with a wide range of applications in medicine, such as the treatment of infections and cancer...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EIN2019-103328
PROGRAMABLE LIVING DRUGS ENGINEERING MICROBIAL CELLS
25K€
Cerrado
Bac3Gel
New generation of substrates to harness the full power of mi...
2M€
Cerrado
PTQ2018-009747
CREACION DE UNA MICROBIOTA INTESTINAL SINTÉTICA PARA EL ESTU...
76K€
Cerrado
MeDiSyn
Scalable Microbial Metabolite Discovery Through Synthetic Bi...
1M€
Cerrado
PTQ-08-03-06248
Desarrollo, mejora y producción de microorganoismos iniciado...
15K€
Cerrado
EEBB-I-12-04372
CONTROL BIOTECNOLOGICO DEL FUEGO BACTERIANO. UTILIZACION DE...
5K€
Cerrado
Información proyecto MiStiC
Duración del proyecto: 64 meses
Fecha Inicio: 2023-04-04
Fecha Fin: 2028-08-31
Líder del proyecto
VIB VZW
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
1M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Bacteria are among the most brilliant chemists on Earth. They are capable of producing a wealth of structurally diverse natural products with a wide range of applications in medicine, such as the treatment of infections and cancer. The synthetic production of microbial natural products and their transformation into pharmaceutical drugs is often a challenging, costly and time-consuming process due to the structural complexity of these molecules and the difficulties associated with drug solubility and formulation.
An emerging new strategy in disease treatment aims to exploit beneficial intestinal microbes for ‘local’ drug production and delivery. Such commensal bacteria are safe, can be administered easily, and can be engineered to detect diseases and release drugs in adequate local concentrations. However, the current therapeutic platform or ‘chassis’ strains cannot stably colonize the human gut and have so far only been engineered to produce therapeutic proteins, such as hormones or cytokines. As a result, no commensal chassis strains are available to treat chronic intestinal diseases or to produce clinically important natural product therapeutics.
In MiStiC, I propose to revolutionize microbial therapy systems by developing the beneficial, stable and prominent gut colonizer Clostridium leptum as an innovative and superior chassis for long-term health monitoring and chronic disease treatment. I will combine my expertise in molecular microbiology, enzyme engineering and natural product biosynthesis to equip the chassis with a nanobody-based biosensor and biocontainment modules, and optimize it for the expression of natural product biosynthetic pathways. As a proof-of-concept, we will implement these tools and chassis strains for the detection and treatment of colorectal cancer.
Together, these innovations will have broad translational applications and will pave the way to a new frontier in the field of microbiome engineering and synthetic microbial therapy systems